Lilly Eli & Co Stock Price, News & Analysis

The FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational antibody, donanemab, for treating Alzheimer's disease. This designation accelerates development for drugs showing significant improvement over existing therapies. Preliminary clinical evidence from the Phase 2 TRAILBLAZER-ALZ trial supports this designation. Lilly plans to submit a biologics license application based on these findings later this year. Donanemab targets modified beta amyloid and is currently undergoing further evaluation in a Phase 3 trial, TRAILBLAZER-ALZ 2.

Eli Lilly has launched the Think Talk Treat Migraine™ initiative aimed at improving migraine care and diagnosis. The initiative addresses the gap in recognizing migraine symptoms and facilitates better communication between patients and primary care providers.
Currently in pilot in four metropolitan areas, it includes tools like a checklist and digital migraine management platform, VEGA™. Despite high prevalence, only a small percentage of migraine sufferers receive adequate treatment. Lilly aims to increase awareness and support effective management of migraine.

Eli Lilly and Company (NYSE: LLY) announced a head-to-head clinical trial comparing Emgality (galcanezumab-gnlm), a monthly injectable, with Nurtec ODT (rimegepant), an oral medication, to assess their effectiveness in preventing migraines. This Phase 4 study will evaluate patients diagnosed with episodic migraine, focusing on the reduction of monthly migraine headache days. The trial aims to provide insights for better treatment decisions. Emgality is recognized for its efficacy in achieving substantial reductions in migraine frequency and has supported over 700,000 patients.

Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series on June 18, 2021. The event features a virtual fireside chat with Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific and Medical Officer, at 11:00 a.m. Eastern Time. Investors can access a live audio webcast on Lilly's Investor website, with a replay available for 90 days post-event. Lilly is committed to discovering life-changing medicines and has been a healthcare leader for over a century, enhancing global health and philanthropy.

Eli Lilly and Company (NYSE: LLY) will host a webcast on July 1, 2021, at 10:00 a.m. Eastern Time, to discuss its diabetes portfolio and findings from the tirzepatide SURPASS clinical trial at the American Diabetes Association's Virtual 81st Scientific Sessions. The conference will address next steps for tirzepatide and insights on Lilly's once-weekly basal insulin and early-phase incretins. The event will be accessible via Lilly's investor website, with a replay available afterward.

Eli Lilly announced promising data for Verzenio (abemaciclib) in high-risk early breast cancer and the oral selective estrogen receptor degrader LY3484356 at ASCO 2021. In the Phase 3 monarchE trial, Verzenio combined with endocrine therapy decreased recurrence risk by 38.6% in patients post-neoadjuvant chemotherapy. The trial included 2,056 patients, with a two-year invasive disease-free survival rate of 87.2%. LY3484356's Phase 1a trial showed encouraging safety and efficacy in advanced breast cancer, with a planned Phase 3 study (EMBER-3) to start later this year.

Eli Lilly will attend the Goldman Sachs Healthcare Conference on June 9-10, 2021. Key executives, including Anne White and Jake Van Naarden, will host a virtual fireside chat on June 9 at 8:50 a.m. ET. The session will be accessible via a live audio webcast on Lilly's Investor website, with a replay available for approximately 90 days.

Lilly is committed to developing life-changing medicines and improving disease management worldwide. For more information, visit www.lilly.com.

Eli Lilly and Company (NYSE: LLY) presented findings on migraine care at the AHS 2021 meeting, revealing 45% of participants hesitated to seek treatment. Key insights from the OVERCOME study highlighted barriers to optimal care. Emgality showed greater adherence (51.2%) compared to oral preventive treatments (27.6%). A discrete choice experiment demonstrated patient preference for the Emgality auto-injector. Additionally, REYVOW 100 mg and 200 mg exhibited superior efficacy in pain relief compared to Nurtec and UBRELVY. These findings underscore the need for improved migraine care discussions.